The global peripheral vascular devices market is expected to enjoy a valuation of US$ 4.7 Billion by the end of the year 2022, and further expand at a CAGR of 6.6% to reach a valuation of US$ 8.9 Billion by the year 2032. According to a recent study by Future Market Insights, peripheral vascular stents are leading the market with a share of about 78.5% in the year 2021, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2021 | US$ 4.5 Billion |
| Market Value 2022 | US$ 4.7 Billion |
| Market Value 2032 | US$ 8.9 Billion |
| CAGR 2022 to 2032 | 6.6% |
| Market Share of Top 5 Countries | 57.6% |
| Key Market Players | Abbott Laboratories; Boston Scientific Corporation; Cook Medical Inc.; MicroPort Scientific Corporation (Endovastec™); Medtronic Plc.; Cardinal Health, Inc.; B. Braun Melsungen AG; BIOTRONIK SE & Co. KG; Becton, Dickinson, and Company; W. L. Gore & Associates Inc.; Getinge AB; Terumo Corp; Kyoto Medical Planning Co Ltd; iVascular S.L.U; AMG International GmbH; ENDOCOR GmbH; Meril Life Sciences Pvt. Ltd.; Nano Therapeutics Pvt Ltd; Koninklijke Philips N.V.; REVA Medical |
Plaque in the arteries that carry blood to the body is the primary cause of peripheral arterial disease (PAD). It generally suggests systemic atherosclerosis and an elevated risk of cardiovascular events. Diabetic patients, smokers, the elderly, and those with cardiovascular disease are most vulnerable to PAD. About half of the persons with PAD are asymptomatic, regardless of whether it causes symptoms, PAD can imply systemic atherosclerosis and an elevated risk of heart disease and stroke. Many novel technologies, as well as new versions of existing devices, are now available for endovascular, less invasive treatment of PAD.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for peripheral vascular devices was approximately 52.0% of the overall US$ 8.6 Billion of the global stents market in 2021. The sales of peripheral vascular devices expanded at a CAGR of 4.4% from 2012 to 2021, owing to a high incidence of cardiovascular disease burden, globally.
Minimally invasive endovascular procedures to expand the artery opening, such as angioplasty or atherectomy, are currently employed more frequently than bypass surgery as the initial treatment strategy for PAD. The two primary forms of endovascular therapies for PAD are balloon angioplasty with stenting and atherectomy. Endovascular therapy or vascular surgery can be used to treat patients with severe PAD.
A large volume of the population worldwide suffers from critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD). While endovascular therapy has been the first choice of treatment in the majority of cases, there is still a range of barriers to the best treatment of diseases such as infrapopliteal (IP) disease.
Endovascular therapy outcomes have significantly improved as technology has advanced. Several innovative technologies are now being developed, including intravascular lithotripsy, percutaneous femoropopliteal bypass, paclitaxel-eluting stents, and the adventitial delivery of anti-restenosis medicines.
As the world's population has grown, so has the demand for healthcare services. Due to an increase in the senior population, the number of individuals suffering from cardiovascular disorders has continually increased. As a result, the demand for devices used in the treatment of cardiovascular disorders has increased. Peripheral vascular devices can be used to treat a variety of heart and arterial problems.
Additionally, technological developments have had a favorable impact on the market shares for peripheral vascular devices. Moreover, the rapid growth of the healthcare industry in developing nations has a beneficial impact on the peripheral vascular devices market growth.
Thus, owing to the aforementioned factors, the global peripheral vascular devices market is expected to grow at a CAGR of 6.6% during the forecast period from 2022 to 2032.
The market for peripheral vascular devices is set to be presented with opportunistic growth over the forecast period. This growth is expected to be owed to the introduction of novel products, such as upgraded drug-eluting vascular stents.
The FDA granted Boston Scientific an investigational device exemption (IDE) in 2015 to initiate a global, pivotal study of the Eluvia drug-eluting stent. EluviaTM Drug-Eluting Vascular Stent System was designed exclusively for the treatment of peripheral artery disease, and in 2018, the USA Food and Drug Administration (FDA) authorized its Premarket Approval (PMA) application.
Stents were first created as a tube that could be inserted intraluminally out of a metal alloy. Bare metal stents (BMSs), coated stents, and drug-eluting stents (DESs) are all types of stents that have evolved in recent years. They may also be self-expanding and balloon expandable. Stents are currently mostly made of nickel and titanium, stainless steel, cobalt chromium, or nickel and titanium.
Biodegradable polymers have been used to create bioabsorbable stents. Although the concept of a bioabsorbable material holds promise, it has not been established in randomized controlled studies and has not demonstrated enhanced or equivalent patency when compared to endarterectomy and PTA.
With the research and development required to improve the outcomes over more standardized approaches, the key players are presented with lucrative prospects for advancement.
Principal Consultant
The growth of the peripheral vascular devices market is restricted by factors that include device recall activities, device limitations, and the high cost of advanced devices. Medtronic issued the FDA’s most serious type of medical device recall, Class I, in response to reports of injuries associated with its HawkOne system for clearing blocked arteries. About 95,000 devices sold to the United States of America since 2018 were subject to the recall, which Medtronic announced in early December 2021. Moreover, the material cost composition of peripheral vascular devices is greater within institutional settings, and the high-cost burden of adoption of these devices is a factor, which hinders the overall market.
Additionally, device limitations during the surgical procedure further pose a restrictive impact on the market expansion. Several procedures utilizing drug-eluting balloons come with the risk of occurrence of restenosis after treatment.
Keeping the above factors into consideration, the global market for peripheral vascular stents is subject to repression, in terms of growth, over the forecast period.
The USA dominates the North American region with a total market share of about 94.5% in 2021 and is expected to continue to experience the same growth throughout the forecast period. With a large population suffering from cardiovascular disorders, the product adoption rate for peripheral vascular devices is quite high within the country, thus propelling the USA into being the largest contributor towards the growth of the global peripheral vascular stents market.
China holds approximately 56.5% share of the East Asia market in 2021 and is projected to display growth at a lucrative CAGR of 8.5% during the forecast period. China presents lucrative prospects for the growth of the overall market, owing to a prospective, multicenter, randomized, and controlled, superiority trial done at 14 hospitals in China as part of the FREEWAY-CHINA project.
The objective of this study was to assess the effectiveness and safety of the FREEWAY paclitaxel-coated balloon. According to the study, the FREEWAY paclitaxel-coated balloon outperformed the uncoated balloon in Chinese patients' target lesion revascularization at the 6- and 12-month mark. With established device adaptability and efficacy in the demographic, the market is poised to be fuelled by future product adoption within the country.
Germany is set to exhibit a CAGR of nearly 6.0% in the European peripheral vascular devices market during the forecast period. The market expansion in Germany is owed to the large geriatric population, advanced medical device technology and research, and a high prevalence of chronic diseases.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Peripheral vascular stents are expected to present high growth at a CAGR of 6.0% by the end of the forecast period. With angioplasty procedures, the use of peripheral vascular stents is adapted for implantation into the artery for the removal of calcified lesions. A large disease population globally calls for a greater number of procedures involving the adoption of peripheral vascular stents, thus promoting this segment’s overall market value.
Peripheral arterial disease holds a revenue share of 30.3% in the global market in 2021. Growing urban lifestyle, as well as a large population consuming alcohol and tobacco, are factors propelling the development of peripheral arterial disease. This segment thus holds a major focus within the market.
iliac artery holds a global revenue share of around 48.1% in 2021. Claudication and/or critical limb ischemia are primarily caused by aortoiliac disease, which has a prevalence of up to 10% in the general population and up to 20% in people over the age of 70 (Annals of Vascular Surgery, 2017). Peripheral artery disease includes aortoiliac occlusive disease.
A substantial portion of the global market for peripheral vascular devices is focused on the iliac artery segment due to increased concerns about this condition.
Hospitals hold the highest market share of about 60.4% during the year 2021. The growing prevalence of chronic and infectious diseases, as well as the associated increasing volumes of surgical procedures, have driven this segment to be a dominant fragment, propelling sales of the overall peripheral vascular devices market.
The overall market is highly fragmented, with multiple rivals in the peripheral vascular device production sphere. These companies are using techniques such as mergers and acquisitions, partnerships and collaborations, and new product releases to meet consumer demand and expand their customer base.
Similarly, recent developments related to companies manufacturing peripheral vascular devices, have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, North Africa, and South Africa |
| Key Market Segments Covered | Product, Indication, Artery, End User, and Region |
| Key Companies Profiled | Abbott Laboratories; Boston Scientific Corporation; Cook Medical Inc.; MicroPort Scientific Corporation (Endovastec™); Medtronic Plc.; Cardinal Health, Inc.; B. Braun Melsungen AG; BIOTRONIK SE & Co. KG; Becton, Dickinson, and Company; W. L. Gore & Associates Inc.; Getinge AB; Terumo Corp; Kyoto Medical Planning Co Ltd; iVascular S.L.U; AMG International GmbH; ENDOCOR GmbH; Meril Life Sciences Pvt. Ltd.; Nano Therapeutics Pvt Ltd; Koninklijke Philips N.V.; REVA Medical |
| Pricing | Available upon Request |
The global peripheral vascular devices market is worth US$ 4.5 Billion in 2021 and is set to expand 1.9X over the next ten years.
The peripheral vascular devices market is expected to reach US$ 8.9 Billion by the end of 2032, with sales revenue expected to register 6.6% CAGR.
The growing burden of cardiovascular diseases, rising awareness regarding cardiovascular procedures, and the adoption of minimally invasive surgical techniques are some of the key trends in this market.
The USA, China, Germany, the United Kingdom, and India are expected to drive demand for the peripheral vascular devices industry.
Demand for peripheral vascular devices in South Asia is expected to register a 7.1% CAGR over the next ten years.
North America is one of the key markets for peripheral vascular devices, with the USA accounting for about 94.5% of the North American peripheral vascular devices market in the year 2021.
Demand for peripheral vascular devices in Europe is expected to register a 6.2% CAGR over the next ten years.
The USA, China, and Germany are the key producers of peripheral vascular devices.
Demand for peripheral vascular devices in the Middle East and Africa(MEA) is expected to register a 5.7% CAGR over the next ten years.
Abbott Laboratories, Boston Scientific Corporation, Cook Medical Inc., MicroPort Scientific Corporation (Endovastec™), Medtronic Plc., Cardinal Health, Inc., B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Becton, Dickinson and Company, W. L. Gore & Associates Inc., Getinge AB, Terumo Corp, Kyoto Medical Planning Co Ltd, iVascular S.L.U, AMG International GmbH, ENDOCOR GmbH, Meril Life Sciences Pvt. Ltd., Nano Therapeutics Pvt Ltd, Koninklijke Philips N.V., and REVA Medical, are some of the key pl
1. Executive Summary | Peripheral Vascular Devices Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USP Analysis
4.3. Key Strategies adopted by manufacturers
4.4. Regulatory Scenario
4.5. Technology Assessment
4.6. Value Chain Analysis
4.7. Recent Product Launches
4.8. PESTLE Analysis
4.9. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Stent Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Number of Peripheral Surgeries
5.2.2. Technological Advancements
5.2.3. Regulatory Landscape
5.2.4. Cost of Procedures
5.2.5. Product Adoption Rate and Demand
5.2.6. Increase in Research and Development
5.2.7. Pharmaceutical Industry Consolidation Activities
5.2.8. Top Companies’ Historical Growth
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Indication
6.1.3. By Artery
6.1.4. By End User
6.1.5. By Region
6.2. 2021 Market Scenario
7. Global Market Volume (Thousands) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Volume (Thousands) Analysis, 2012 to 2021
7.2. Current and Future Market Volume (Thousands) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Pricing Break Up
8.2.1. Manufacturer Level
8.2.2. Distributor Level
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
9.1. Historical Market Value (US$ Million) Analysis 2012 to 2021
9.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Product, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Product, 2022 to 2032
10.3.1. Peripheral Vascular Stents
10.3.1.1. Self-Expanding Stents
10.3.1.2. Balloon Expanding Stents
10.3.1.3. Covered Stents
10.3.1.4. Drug Eluting Stents
10.3.2. Drug Eluting Balloons
10.3.3. Peripheral Vascular Bioresorbable Scaffolds
10.4. Market Attractiveness Analysis By Product
11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2022 to 2032
11.3.1. Target Artery Instability (TAI)
11.3.2. Access Artery Injury (AAI)
11.3.3. Peripheral Arterial Disease
11.3.4. Arteriovenous Fistulas
11.3.5. Peripheral Aneurysms
11.3.6. Others
11.4. Market Attractiveness Analysis By Indication
12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Artery
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Artery, 2012 to 2021
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Artery, 2022 to 2032
12.3.1. Carotid Artery
12.3.2. Fem-Pop Artery
12.3.3. Iliac Artery
12.3.4. Infrapop Artery
12.4. Market Attractiveness Analysis By Artery
13. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2021
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers/Outpatients
13.3.3. Cardiac Catheterization Labs
13.4. Market Attractiveness Analysis By End User
14. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Region, 2012 to 2021
14.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Region, 2022 to 2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East & Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Region, 2012 to 2021
15.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Region, 2022 to 2032
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Indication
15.3.4. By Artery
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Product
15.4.2. By Indication
15.4.3. By Artery
15.4.4. By End User
15.4.5. By Country
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country-Level Analysis & Forecast
15.8.1. USA Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Indication
15.8.1.2.3. By Artery
15.8.1.2.4. By End User
15.8.2. Canada Market
15.8.3. Introduction
15.8.4. Market Analysis and Forecast by Market Taxonomy
15.8.4.1.1. By Product
15.8.4.1.2. By Indication
15.8.4.1.3. By Artery
15.8.4.1.4. By End User
16. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021
16.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Indication
16.3.4. By Artery
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Product
16.4.2. By Indication
16.4.3. By Artery
16.4.4. By End User
16.4.5. By Country
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country-Level Analysis & Forecast
16.8.1. Brazil Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Indication
16.8.1.2.3. By Artery
16.8.1.2.4. By End User
16.8.2. Mexico Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Indication
16.8.2.2.3. By Artery
16.8.2.2.4. By End User
16.8.3. Argentina Market
16.8.4. Introduction
16.8.5. Market Analysis and Forecast by Market Taxonomy
16.8.5.1. By Product
16.8.5.2. By Indication
16.8.5.3. By Artery
16.8.5.4. By End User
17. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021
17.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. United Kingdom
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Nordic Countries
17.3.1.9. Rest of Europe
17.3.2. By Product
17.3.3. By Indication
17.3.4. By Artery
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Product
17.4.2. By Indication
17.4.3. By Artery
17.4.4. By End User
17.4.5. By Country
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country-Level Analysis & Forecast
17.8.1. Germany Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Indication
17.8.1.2.3. By Artery
17.8.1.2.4. By End User
17.8.2. Italy Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Indication
17.8.2.2.3. By Artery
17.8.2.2.4. By End User
17.8.3. France Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Indication
17.8.3.2.3. By Artery
17.8.3.2.4. By End User
17.8.4. United Kingdom Market
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Indication
17.8.4.2.3. By Artery
17.8.4.2.4. By End User
17.8.5. Spain Market
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Product
17.8.5.2.2. By Indication
17.8.5.2.3. By Artery
17.8.5.2.4. By End User
17.8.6. BENELUX Market
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Product
17.8.6.2.2. By Indication
17.8.6.2.3. By Artery
17.8.6.2.4. By End User
17.8.7. Russia Market
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Product
17.8.7.2.2. By Indication
17.8.7.2.3. By Artery
17.8.7.2.4. By End User
17.8.8. Nordic Countries Market
17.8.8.1. Introduction
17.8.8.2. Market Analysis and Forecast by Market Taxonomy
17.8.8.2.1. By Product
17.8.8.2.2. By Indication
17.8.8.2.3. By Artery
17.8.8.2.4. By End User
18. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021
18.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Indication
18.3.4. By Artery
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Product
18.4.2. By Indication
18.4.3. By Artery
18.4.4. By End User
18.4.5. By Country
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. China Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Indication
18.8.1.2.3. By Artery
18.8.1.2.4. By End User
18.8.2. Japan Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Indication
18.8.2.2.3. By Artery
18.8.2.2.4. By End User
18.8.3. South Korea Market
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product
18.8.3.2.2. By Indication
18.8.3.2.3. By Artery
18.8.3.2.4. By End User
19. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021
19.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Rest of South Asia
19.3.2. By Product
19.3.3. By Indication
19.3.4. By Artery
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Product
19.4.2. By Indication
19.4.3. By Artery
19.4.4. By End User
19.4.5. By Country
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country-Level Analysis & Forecast
19.8.1. India Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Indication
19.8.1.2.3. By Artery
19.8.1.2.4. By End User
19.8.2. Indonesia Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Indication
19.8.2.2.3. By Artery
19.8.2.2.4. By End User
19.8.3. Malaysia Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Indication
19.8.3.2.3. By Artery
19.8.3.2.4. By End User
19.8.4. Thailand Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Indication
19.8.4.2.3. By Artery
19.8.4.2.4. By End User
20. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021
20.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Indication
20.3.4. By Artery
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Product
20.4.2. By Indication
20.4.3. By Artery
20.4.4. By End User
20.4.5. By Country
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country-Level Analysis & Forecast
20.8.1. Australia Market
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Product
20.8.1.2.2. By Indication
20.8.1.2.3. By Artery
20.8.1.2.4. By End User
20.8.2. New Zealand Market
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Product
20.8.2.2.2. By Indication
20.8.2.2.3. By Artery
20.8.2.2.4. By End User
21. Middle East and Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032
21.1. Introduction
21.2. Historical Market Size (US$ Million) and Volume (Thousands) Analysis By Market Taxonomy, 2012 to 2021
21.3. Current and Future Market Size (US$ Million) and Volume (Thousands) Analysis and Forecast By Market Taxonomy, 2022 to 2032
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Turkey
21.3.1.3. Israel
21.3.1.4. North Africa
21.3.1.5. South Africa
21.3.1.6. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Indication
21.3.4. By Artery
21.3.5. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Product
21.4.2. By Indication
21.4.3. By Artery
21.4.4. By End User
21.4.5. By Country
21.5. Market Trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country-Level Analysis & Forecast
21.8.1. GCC Countries Market
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Product
21.8.1.2.2. By Indication
21.8.1.2.3. By Artery
21.8.1.2.4. By End User
21.8.2. Turkey Market
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Product
21.8.2.2.2. By Indication
21.8.2.2.3. By Artery
21.8.2.2.4. By End User
21.8.3. Israel Market
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Product
21.8.3.2.2. By Indication
21.8.3.2.3. By Artery
21.8.3.2.4. By End User
21.8.4. North Africa Market
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Product
21.8.4.2.2. By Indication
21.8.4.2.3. By Artery
21.8.4.2.4. By End User
21.8.5. South Africa Market
21.8.5.1. Introduction
21.8.5.2. Market Analysis and Forecast by Market Taxonomy
21.8.5.2.1. By Product
21.8.5.2.2. By Indication
21.8.5.2.3. By Artery
21.8.5.2.4. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis (%) of Top Players
22.3. Market Presence Analysis
22.3.1. Regional Footprint by Players
22.3.2. Product Footprint by Players
22.3.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Abbott Laboratories
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Sales Footprint
23.3.1.4. Key Financials
23.3.1.5. SWOT Analysis
23.3.1.6. Strategy Overview
23.3.1.6.1. Marketing Strategy
23.3.1.6.2. Product Strategy
23.3.1.6.3. Channel Strategy
23.3.2. Boston Scientific Corporation
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Sales Footprint
23.3.2.4. Key Financials
23.3.2.5. SWOT Analysis
23.3.2.6. Strategy Overview
23.3.2.6.1. Marketing Strategy
23.3.2.6.2. Product Strategy
23.3.2.6.3. Channel Strategy
23.3.3. Cook Medical Inc.
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Sales Footprint
23.3.3.4. Key Financials
23.3.3.5. SWOT Analysis
23.3.3.6. Strategy Overview
23.3.3.6.1. Marketing Strategy
23.3.3.6.2. Product Strategy
23.3.3.6.3. Channel Strategy
23.3.4. MicroPort Scientific Corporation (Endovastec™)
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Sales Footprint
23.3.4.4. Key Financials
23.3.4.5. SWOT Analysis
23.3.4.6. Strategy Overview
23.3.4.6.1. Marketing Strategy
23.3.4.6.2. Product Strategy
23.3.4.6.3. Channel Strategy
23.3.5. Medtronic Plc.
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Sales Footprint
23.3.5.4. Key Financials
23.3.5.5. SWOT Analysis
23.3.5.6. Strategy Overview
23.3.5.6.1. Marketing Strategy
23.3.5.6.2. Product Strategy
23.3.5.6.3. Channel Strategy
23.3.6. Cardinal Health, Inc.
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Sales Footprint
23.3.6.4. Key Financials
23.3.6.5. SWOT Analysis
23.3.6.6. Strategy Overview
23.3.6.6.1. Marketing Strategy
23.3.6.6.2. Product Strategy
23.3.6.6.3. Channel Strategy
23.3.7. B. Braun Melsungen AG
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Sales Footprint
23.3.7.4. Key Financials
23.3.7.5. SWOT Analysis
23.3.7.6. Strategy Overview
23.3.7.6.1. Marketing Strategy
23.3.7.6.2. Product Strategy
23.3.7.6.3. Channel Strategy
23.3.8. BIOTRONIK SE & Co. KG
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Sales Footprint
23.3.8.4. Key Financials
23.3.8.5. SWOT Analysis
23.3.8.6. Strategy Overview
23.3.8.6.1. Marketing Strategy
23.3.8.6.2. Product Strategy
23.3.8.6.3. Channel Strategy
23.3.9. Becton, Dickinson, and Company
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Sales Footprint
23.3.9.4. Key Financials
23.3.9.5. SWOT Analysis
23.3.9.6. Strategy Overview
23.3.9.6.1. Marketing Strategy
23.3.9.6.2. Product Strategy
23.3.9.6.3. Channel Strategy
23.3.10. W. L. Gore & Associates Inc.
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Sales Footprint
23.3.10.4. Key Financials
23.3.10.5. SWOT Analysis
23.3.10.6. Strategy Overview
23.3.10.6.1. Marketing Strategy
23.3.10.6.2. Product Strategy
23.3.10.6.3. Channel Strategy
23.3.11. Getinge AB
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Sales Footprint
23.3.11.4. Key Financials
23.3.11.5. SWOT Analysis
23.3.11.6. Strategy Overview
23.3.11.6.1. Marketing Strategy
23.3.11.6.2. Product Strategy
23.3.11.6.3. Channel Strategy
23.3.12. Terumo Corp
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Sales Footprint
23.3.12.4. Key Financials
23.3.12.5. SWOT Analysis
23.3.12.6. Strategy Overview
23.3.12.6.1. Marketing Strategy
23.3.12.6.2. Product Strategy
23.3.12.6.3. Channel Strategy
23.3.13. Kyoto Medical Planning Co Ltd
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Sales Footprint
23.3.13.4. Key Financials
23.3.13.5. SWOT Analysis
23.3.13.6. Strategy Overview
23.3.13.6.1. Marketing Strategy
23.3.13.6.2. Product Strategy
23.3.13.6.3. Channel Strategy
23.3.14. iVascular S.L.U
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Sales Footprint
23.3.14.4. Key Financials
23.3.14.5. SWOT Analysis
23.3.14.6. Strategy Overview
23.3.14.6.1. Marketing Strategy
23.3.14.6.2. Product Strategy
23.3.14.6.3. Channel Strategy
23.3.15. AMG International GmbH
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Sales Footprint
23.3.15.4. Key Financials
23.3.15.5. SWOT Analysis
23.3.15.6. Strategy Overview
23.3.15.6.1. Marketing Strategy
23.3.15.6.2. Product Strategy
23.3.15.6.3. Channel Strategy
23.3.16. ENDOCOR GmbH
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Sales Footprint
23.3.16.4. Key Financials
23.3.16.5. SWOT Analysis
23.3.16.6. Strategy Overview
23.3.16.6.1. Marketing Strategy
23.3.16.6.2. Product Strategy
23.3.16.6.3. Channel Strategy
23.3.17. Meril Life Sciences Pvt. Ltd.
23.3.17.1. Overview
23.3.17.2. Product Portfolio
23.3.17.3. Sales Footprint
23.3.17.4. Key Financials
23.3.17.5. SWOT Analysis
23.3.17.6. Strategy Overview
23.3.17.6.1. Marketing Strategy
23.3.17.6.2. Product Strategy
23.3.17.6.3. Channel Strategy
23.3.18. Nano Therapeutics Pvt Ltd
23.3.18.1. Overview
23.3.18.2. Product Portfolio
23.3.18.3. Sales Footprint
23.3.18.4. Key Financials
23.3.18.5. SWOT Analysis
23.3.18.6. Strategy Overview
23.3.18.6.1. Marketing Strategy
23.3.18.6.2. Product Strategy
23.3.18.6.3. Channel Strategy
23.3.19. Koninklijke Philips N.V.
23.3.19.1. Overview
23.3.19.2. Product Portfolio
23.3.19.3. Sales Footprint
23.3.19.4. Key Financials
23.3.19.5. SWOT Analysis
23.3.19.6. Strategy Overview
23.3.19.6.1. Marketing Strategy
23.3.19.6.2. Product Strategy
23.3.19.6.3. Channel Strategy
23.3.20. REVA Medical
23.3.20.1. Overview
23.3.20.2. Product Portfolio
23.3.20.3. Sales Footprint
23.3.20.4. Key Financials
23.3.20.5. SWOT Analysis
23.3.20.6. Strategy Overview
23.3.20.6.1. Marketing Strategy
23.3.20.6.2. Product Strategy
23.3.20.6.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Peripheral Vascular Devices Market
